Am J Transplant, Volume 18, Suppl 3 Archives - Page 168 of 211 - ATC Abstracts

2018 American Transplant Congress
Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant
Y. Lu,¹ J. Lyons,² S. Tischer,² K. Woodside,³ J. Park.²
¹Transplant Nephrology, University of Michigan, Ann Arbor, MI; ²Transplant Pharmacy, University of Michigan, Ann Arbor, MI; ³Transplant Surgery, University of Michigan, Ann Arbor, MI.
Background: For patients with end stage renal disease (ESRD) due to primary focal segmental glomerulosclerosis (FSGS), there is a significantly increased risk for disease recurrence…
2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
M. Benincasa,¹ V. Colomy,¹ N. Sifontis,¹ S. Rao,² K. Lau,³ S. Karhadkar,³ A. Di Carlo,³ A. Diamond.⁴
¹Pharmacy Practice, Temple School of Pharmacy, Philadelphia, PA; ²Medicine, Temple School of Medicine, Philadelphia, PA; ³Surgery, Temple School of Medicine, Philadelphia, PA; ⁴Pharmacy, Temple University Hospital, Philadelphia, PA.
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…
2018 American Transplant Congress
Evaluation of Financial Well-Being of Living Kidney Donor Candidates
S. Singh,^1,2 G. Bannerman,² A. Yantsis,² M. Liu,² F. Gumabay,² O. Famure.²
¹Division of Nephrology, Department of Medicine, University of Toronto, Toronto, ON, Canada; ²Division of Nephrology and the Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Despite the known benefits of living donor kidney transplantation, the rate of living kidney donation in Canada has not increased. Potential reasons include the lack…
2018 American Transplant Congress
Outcomes in Living Kidney Transplant Donor and Recipient Operations with Same vs. Different Surgeons
J. Sokolich,¹ J. Buggs,¹ D. Mahon,² E. Rogers,³ V. Bowers.¹
¹Transplant Surgery, Tampa General Medical Group, Tampa General Hospital, Tampa, FL; ²Pre-Med Undergraduate, University of South Florida, Tampa, FL; ³Transplant Research, Tampa General Hospital, Tampa, FL.
Introduction: Living Kidney Transplantation (LKT) has provided a means of increasing the organ pool for patients with end-stage renal disease (ESRD). Surgical practices vary regarding…
2018 American Transplant Congress
Hemodialysis Catheter-Related Right Atrial Thrombus Detected Prior to Kidney Transplantation
S. Jeung, H. Kim, C. Baek, S-.K. Park.
Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea.
Study's purposeThe study was conducted to review the clinical characteristics, management, and outcomes of patients with hemodialysis catheter-related right atrial thrombus (RAT) detected prior to…
2018 American Transplant Congress
Minimal Invasive Surgery is Feasible and Safe in Patients with Liver and Kidney Transplant Patients
W. Yin.
Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan; School of Medicine Tzu Chi University, Hualien, Taiwan.
Introduction: It is no doubt that laparoscopic surgery nowadays is widely used in many abdominal surgical procedures from laparoscopic cholecystectomy to Whipple procedure. However, there…
2018 American Transplant Congress
Prevalence, Risk Factors and Impact of BK Viremia on Kidney Transplantation: Single Center Experience
W. Hassan, A. El-Husseini, B. Suleiman, K. Wang, M. Yaseen, A. Maibam, A. Karim, A. Hines, A. Castellanos, V. Cornea, X. Mei, R. Gedaly, T. Waid.
Nephrology, University of Kentucky, Lexington, KY.
Introduction: BK viremia (BKV) is an emerging problem in renal transplantation. The risk factors and the impact of BKV on renal allograft and patient survival…
2018 American Transplant Congress
Side Effect Profile of Everolimus in Liver Transplant Patients
F. Kumssa, O. Sadiq, M. Alimirah, R. Kaur, A. Patel, S-.M. Jafri.
Henry Ford Hospital, Detroit.
IntroductionUse of calcineurin inhibitors has been the mainstay of antirejection medications after liver transplant (LT). However, renal toxicity from these drugs remains troublesome. By comparison,…
2018 American Transplant Congress
The Impact of a Tobacco Prohibition Policy Compared to a Restrictive Policy on Liver Transplant Candidate Outcomes
A. Likhitsup,¹ A. Hassan,¹ J. Mellinger,¹ F. Askari,¹ G. Winder,² P. Sharma,¹ N. Saeed,³ C. Sonnenday,⁴ R. Fontana.¹
¹Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI; ²Department of Psychiatry, University of Michigan, Ann Arbor, MI; ³Department of Internal Medicine, Beaumont Hospital, Dearborn, MI; ⁴Department of Surgery, University of Michigan, Ann Arbor, MI.
Introduction: Substance use disorders (SUD) are common in liver transplant (LT) candidates. Poorer postLT outcomes in tobacco users have led programs to prohibit tobacco use…
2018 American Transplant Congress
Impact of Early Corticosteroid Treatment in Patients with Indeterminate Acute Severe Hepatitis
E. Mohr,¹ R. Sucher,² T. Müller,³ T. Kaiser,⁴ T. Berg.¹
¹Hepatology, University Clinic Leipzig, Leipzig, Germany; ²Transplant Surgery, University Clinic Leipzig, Leipzig, Germany; ³Hepatology, Charite, Berliin, Germany; ⁴Laboratory Diagnostics, University Clinic Leipzig, Leipzig, Germany.
Background and Aims: Discrimination of acute severe autoimmune hepatitis AIH and drug induced liver injury in patients with indeterminate acute severe Hepatitis is challenging. Early…